PMC5760870_01
(a) Phase I contouring showing planning target volume 1 and planning target volume 2 with fluorodeoxyglucose-positron emission tomography co-registration. (b) Phase II contouring with planning target volume n
LI-35-54-g001.jpg
PMC5760870_01_LI-35-54-g001.jpg
F1
PTVn margins were reduced accordingly (PTV2 was removed). PTVn was prescribed 16 Gy at 2 Gy per fraction [Figure 1].
(a) Dose-color wash denoting Phase I and Phase II, respectively. (b) Dose-volume histogram showing Phase I planning target volume 1 and planning target volume 2. (c) Dose-volume histogram showing Phase II planning target volume n
LI-35-54-g005.jpg
PMC5760870_01_LI-35-54-g005.jpg
F2
(a) Response evaluation with fluorodeoxyglucose-positron emission tomography at 12 weeks of completion of radiotherapy. (b) Response evaluation with fluorodeoxyglucose-positron emission tomography at 20 weeks of completion of radiotherapy
LI-35-54-g006.jpg
PMC5760870_01_LI-35-54-g006.jpg
F3
No detrimental changes were noted in the PFTs and CT thorax at 12- and 20-week postradiotherapy [Figure 3].